1. Ekambaram P, Abdul Hasan Sathali A, Priyanka K. Solid lipid nanoparticles: a review. Sci Revs ChemCommun 2012; 2: 80-102.
2. Gonnet M, Lethuaut L, Boury F. New trends in encapsulation of liposoluble vitamins. J Control Release 2010; 146: 276–90 https://doi.org/10.1016/j.jconrel.2010.01.037
3. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996; 13: 257-388. https://doi.org/10
Enciu Manuela, Bălțătescu Gabriela Izabela, Mocanu Liliana and Burlacu Ionuț
1. Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006 Sep 15;107(6):1255-64.
2. Chan JK. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma [editorial]. Am J Clin Pathol. 2002;117:16-18) (Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002;117:143-150.
Hydrogels are cross-linked hydrophilic polymer networks that can contain a high amount of water. Their hydrated network architecture provides a place for cells to adhere, proliferate, and differentiate. They are generally nontoxic and biocompatible. In tissue engineering, hydrogels can be used to encapsulate living cells as a cell delivery system and as a scaffold for tissue regeneration. Moreover, hydrogels can be delivered to a target site in a minimally invasive manner. Nevertheless, the gelling process must be benign for cell survival and to avoid damage to
An article published online on April 14, 2016, in JAMA Oncology [ 1 ] proposed that “a paradigm shift to reduce overtreatment of indolent tumors” is to be created by changing the name of encapsulated follicular variant papillary thyroid carcinoma (EFVPTC) to “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” (NIFTP). This revised nomenclature essentially reclassifies these tumors from the current status as “low risk” or “very low risk” cancers to being not cancers at all. The article has been viewed some 80,000 times online and has
4. Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA - Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid. 2009;19(2):119-127.
5. Rivera M, Ricarte-Filho J, Knauf J et al. - Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010;23(9):1191-1200.
6. Vivero M, Kraft S
Erna Schönthaler, Petra Schwab, Monika Zettel-Tomenendal and Valentin Ritschl
attitude towards EBP
Participant B encapsulated the central topic of this subcategory by quoting ‘it aroused such an eagerness , to re-examine’ (B:831). Several others expressed the increased interest with wordings like ‘I’m curious about EBP, which originated from using the EBP Service Centre’ (E:1498).
Several participants stated that ‘it motivated me to conduct research projects on my own’ (M:214). The participants’ newly emerged willingness to participate in research projects became evident.
‘One suddenly feels like doing research – if you see that so many OT
Nicoleta Todoran, Adriana Ciurba, Emőke Rédai, V. Ion, Luminița Lazăr and Emese Sipos
Chloramphenicol eye drops are commonly prescribed in concentrations of 0.5-1% in the treatment of infectious conjunctivitis. In terms of ophthalmic solution preparation, the major disadvantage of chloramphenicol consists in its low solubility in water. The solubility is increased by substances that form chloramphenicol-complexes, for example: boric acid/borax or cyclodextrins. Objective: Experimental studies aimed to evaluate the potential advantages of enhancing the solubility and stability of chloramphenicol (API) by molecular encapsulation in b-cyclodextrin (CD), in formulation of ophthalmic solutions buffered with boric acid/borax system. Methods and Results: We prepared four APIb- CD complexes, using two methods (kneading and co-precipitation) and two molar ratio of API/b-cyclodextrin (1:1 and 1:2). The formation of complexes was proved by differential scanning calorimetry (DSC) and the in vitro dissolution tests. Using these compounds, we prepared eight ophthalmic solutions, formulated in two variants of chloramphenicol concentrations (0.4% and 0.5%). Each solution was analyzed, by the official methods, at preparation and periodically during three months of storing in different temperature conditions (4°C, 20°C and 30°C). Conclusions: Inclusion of chloramphenicol in b-cyclodextrin only partially solves the difficulties due to the low solubility of chloramphenicol. The protection of chloramphenicol molecules is not completely ensured when the ophthalmic solutions are buffered with the boric acid/borax system.